These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24365533)

  • 1. The misguided ethics of crossover trials.
    Prasad V; Grady C
    Contemp Clin Trials; 2014 Mar; 37(2):167-9. PubMed ID: 24365533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.
    Jönsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jönsson B; Weinstein MC; Drummond M
    Value Health; 2014 Sep; 17(6):707-13. PubMed ID: 25236994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs.
    Goldberg RM; Wei L; Fernandez S
    Oncologist; 2017 Sep; 22(9):1015-1019. PubMed ID: 28620092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target validation using Phase 0 clinical trials: Promises and pitfalls.
    Angelo LS; Kurzrock R
    Cancer Biol Ther; 2009 Nov; 8(21):2010-2. PubMed ID: 20037466
    [No Abstract]   [Full Text] [Related]  

  • 5. Methodological and ethical difficulties in clinical oncology trials. Di Bella Multitreatment Italian Trial Coordinating Group.
    Raschetti R; Bruzzi P
    Lancet; 1999 Jan; 353(9147):153-4. PubMed ID: 10023931
    [No Abstract]   [Full Text] [Related]  

  • 6. Next steps in clinical trial redesign.
    Nicholas J
    J Natl Cancer Inst; 2012 Jan; 104(2):90-2. PubMed ID: 22215851
    [No Abstract]   [Full Text] [Related]  

  • 7. Translational research in clinical trials: the only way forward.
    Eggermont A; Newell H
    Eur J Cancer; 2001 Nov; 37(16):1965. PubMed ID: 11699495
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
    Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
    Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ethics of phase 0 oncology trials.
    Abdoler E; Taylor H; Wendler D
    Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
    Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
    J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethical and Policy Issues for Seamless Phase I Oncology Trials.
    Hutchinson N; Vinarov E; Iasonos A; Kimmelman J
    J Clin Oncol; 2020 Mar; 38(7):669-673. PubMed ID: 31877086
    [No Abstract]   [Full Text] [Related]  

  • 13. Ethical issues on the "synthetic" phosphoethanolamine clinical trial.
    Paumgartten FJR
    Rev Assoc Med Bras (1992); 2017 May; 63(5):388-392. PubMed ID: 28724033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
    Theoret MR; Pai-Scherf LH; Chuk MK; Prowell TM; Balasubramaniam S; Kim T; Kim G; Kluetz PG; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Oct; 21(20):4545-51. PubMed ID: 26473190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
    Fojo T; Amiri-Kordestani L; Bates SE
    J Natl Cancer Inst; 2011 Dec; 103(23):1738-40. PubMed ID: 22045362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology--44th Annual Meeting. Reports of clinical trial results--part 1.
    Searle B
    IDrugs; 2008 Aug; 11(8):545-6. PubMed ID: 18683083
    [No Abstract]   [Full Text] [Related]  

  • 17. Reviewing concomitant medications for participants in oncology clinical trials.
    McGahey KE; Weiss GJ
    Am J Health Syst Pharm; 2017 Apr; 74(8):580-586. PubMed ID: 28389457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology--44th Annual Meeting. Reports of clinical trial results--part 2.
    Ogbighele E
    IDrugs; 2008 Aug; 11(8):547-9. PubMed ID: 18683084
    [No Abstract]   [Full Text] [Related]  

  • 20. The statistics of phase 0 trials.
    Rubinstein LV; Steinberg SM; Kummar S; Kinders R; Parchment RE; Murgo AJ; Tomaszewski JE; Doroshow JH
    Stat Med; 2010 May; 29(10):1072-6. PubMed ID: 20419759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.